MRK

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.

Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.

Merck & Co., Inc. NYSE: MRK reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield.

The Dow Dogs remain broadly overvalued, with none meeting the ideal 'fair price' threshold where dividends from $1K invested exceed share price. Analyst forecasts suggest the top ten Dow Dogs could deliver 18.3% to 54.76% net gains by August 2027, with an average projected return of 29.64%. Only 21 of 30 Dow stocks are considered 'safer' for dividends, supported by free cash flow; Nike is closest to 'ideal' but still has a negative safety margin.

Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.

Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.